Scaling up diagnostic-driven management of sexually transmitted infections in pregnancy. by Wynn, Adriane et al.
UCLA
UCLA Previously Published Works
Title
Scaling up diagnostic-driven management of sexually transmitted infections in pregnancy.
Permalink
https://escholarship.org/uc/item/7gw060f5
Journal
The Lancet. Infectious diseases, 19(8)
ISSN
1473-3099
Authors
Wynn, Adriane
Moucheraud, Corrina
Morroni, Chelsea
et al.
Publication Date
2019-08-01
DOI
10.1016/s1473-3099(19)30351-2
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Scaling up diagnostic driven management of sexually transmitted 
infections in pregnancy 
Curable sexually transmitted infections (STIs), for example Chlamydia 
trachomatis and Neisseria gonorrhoeae, are common worldwide1 and can 
have severe consequences for women and, when occurring in pregnancy, 
their children.2 WHO recommends a syndromic approach to STIs in low 
resource settings where laboratory services are scarce, but this approach 
lacks sensitivity and specificity, missing many infections and causing 
overtreatment. 
An Article by Marijn C Verwijs and colleagues3 found that incorporating 
point-of-care (POC) STI testing with GeneXpert into case-finding and infection
management improved identification of true infections and prevented 
overtreatment among women in Kigali, Rwanda. Similar results have been 
found for Botswana.4 In their Comment on Verwijs and colleagues’ study,3 
Rosanna Wai Wan Peeling and David Mabey5 stated that POC tests have the 
potential to revolutionise STI management, but that the high costs of 
available tests might limit widespread scale-up in the high burden, low-
resource settings where they are needed most. 
We agree that development of lower-cost diagnostics should be 
prioritised and, in the meantime, suggest that implementation research be 
used to identify approaches for expanding access to STI testing. We 
developed a decision model to estimate the 1-year costs and outcomes 
associated with different strategies for scaling-up C trachomatis and N 
gonorrhoeae testing for pregnant women in Botswana.4 We compared 
syndromic management with three POC strategies: GeneXpert-based POC 
testing at all hospitals and clinics providing antenatal care, GeneXpert 
testing at regional hospitals to analyse samples from multiple facilities, and a
hub-and-spoke model whereby high volume sites conduct POC testing and 
serve as hubs for samples collected from other sites in their areas. Our 
results suggest that the strategy of POC testing at every antenatal care 
facility was the most expensive because of large capital costs and might be 
unaffordable for low-income countries.4 Although syndromic management 
was the least expensive strategy, it resulted in fewer infections cured and 
considerable overtreatment. Among testing strategies, we found that the 
hub-and-spoke approach would offer the optimal cost per infection averted. 
Modelling analyses that incorporate system dynamics—ie, patient 
volume, disease burden, infrastructure, and budget effects—could inform 
plans to scale-up testing to improve STI management globally. Our analysis 
suggests strategies for reducing costs and maximising impact by 
strategically situating POC testing. There are additional opportunities for cost
reductions, such as integrating testing into antenatal care services, 
maximising multiplex capacity, and using existing but underused resources, 
such as the GeneXpert Mycobacterium tuberculosis testing network, which 
could reduce capital costs and have important clinical and public health 
benefits. 
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